AI responses may include mistakes. For financial advice, consult a professional. Learn more
As of April 2026, analysts generally hold a moderate buy rating for Gilead Sciences (GILD) , with many forecasting a potential upside from current prices. The company shows strength in its HIV portfolio, including Biktarvy, although some analysts express caution regarding declining revenue from other products. gild buy or sell